spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  vasopressin 

 HSMN NewsFeed - 16 Nov 2020
Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2019
Levo Therapeutics Receives Fast Track Designation From FDA for Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome
Biopharmaceuticals Neurology Drug Delivery FDA
 HSMN NewsFeed - 30 Sep 2019
Endo Announces Successful Culmination of Litigation Regarding FDA Compounding Policy
Biopharmaceuticals Generics FDA Litigation
 HSMN NewsFeed - 15 Aug 2019
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2019
Endo Applauds U.S. District Court Decision that Vasopressin Cannot be Used for Compounding by Outsourcing Facilities
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 15 Aug 2018
Endo Lifts Temporary Stay of FDA Litigation Following the Launch of a Bulk-Compounded Vasopressin Product by a Section 503B Outsourcing Facility
Biopharmaceuticals Generics FDA Litigation
 HSMN NewsFeed - 2 Apr 2018
Endo Agrees to Extend Temporary Stay of FDA Litigation
Biopharmaceuticals FDA Litigation
 HSMN NewsFeed - 7 Mar 2017
U.S. FDA Approves Serenity Pharmaceutical’s Noctiva(TM) (desmopressin acetate) – the First Drug Approved for the Treatment of Nocturia
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jan 2016
Piramal Critical Care and Cumberland Pharmaceuticals Announce Launch of Caldolor and Vaprisol Co-Promotion
Biopharmaceuticals Distribution Product Launch
 HSMN NewsFeed - 12 Nov 2014
Par Pharmaceutical Announces First FDA Approval of Vasostrict(TM) (vasopressin injection, USP)
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Mar 2014
Otsuka Pharmaceutical's Samsca(R) Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Dec 2013
European Medicines Agency (EMA) Accepts Otsuka's Marketing Authorisation Application (MAA) for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Mar 2012
Cornerstone Therapeutics Receives FDA Acceptance for CRTX 080 NDA for Treatment of Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2012
Cornerstone Therapeutics Acquires Cardiokine
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Oct 2009
Amber Salzman Named President and CEO of Cardiokine
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 May 2009
FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Apr 2009
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Apr 2009
Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2008
FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Sep 2008
Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 14 Feb 2008
Biogen Idec and Cardiokine Initiate Phase III Clinical Trial for Lixivaptan in Congestive Heart Failure Patients with Hyponatremia
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Jan 2008
Dr. Manuel Worcel Appointed CEO and President of Cardiokine
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2007
New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Oct 2007
Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2007
Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2007
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 25 Mar 2007
EVEREST Data on Short- and Long-Term Use of Otsuka's Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC's Late Breaking Clinical Trials
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Mar 2007
FDA Approves Astellas' Vaprisol(R) for the Treatment of Hypervolemic Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Nov 2006
New Data on Otsuka's Investigational Product for Hyponatremia Presented at American Heart Association Annual Meeting
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 10

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 10 additional stories matching:
vasopressin
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!